I agree fdaf....You can bet (I am), that the 942 will be unique, exciting and effective The big biotech sell off is providing an opportunity here. I bought handfuls of times under 110 and as low as 83. I have large limit buy in in the 70 cent range.
On 1/1/16 I see it listed if you click "equity", then "Research Universe" and look under Healthcare/Biotech. Listed Aschoff as the analyst.
I bought at 9 ( I which I bought a lot more) . About 300% upside so far, but I did not sell.. Not planning to sell yet. I do a lot of biotech investing.
The most important word in today's conference call was the word "several". I was assuming they were in talks with one party and did not have much leverage. Several means more than two. Here is the quote from the cc. "we are active in ongoing discussions with several parties regarding a partnership for licensing of OHR-102" ----that will give them some leverage.